Yale School of Medicine, New Haven, CT, USA.
VA Connecticut Healthcare Center, West Haven, CT, USA.
Mol Psychiatry. 2022 Oct;27(10):3970-3979. doi: 10.1038/s41380-022-01709-1. Epub 2022 Jul 25.
Despite the large toll of opioid use disorder (OUD), genome-wide association studies (GWAS) of OUD to date have yielded few susceptibility loci. We performed a large-scale GWAS of OUD in individuals of European (EUR) and African (AFR) ancestry, optimizing genetic informativeness by performing MTAG (Multi-trait analysis of GWAS) with genetically correlated substance use disorders (SUDs). Meta-analysis included seven cohorts: the Million Veteran Program, Psychiatric Genomics Consortium, iPSYCH, FinnGen, Partners Biobank, BioVU, and Yale-Penn 3, resulting in a total N = 639,063 (N = 20,686;N = 77,026) across ancestries. OUD cases were defined as having a lifetime OUD diagnosis, and controls as anyone not known to meet OUD criteria. We estimated SNP-heritability (h) and genetic correlations (r). Based on genetic correlation, we performed MTAG on OUD, alcohol use disorder (AUD), and cannabis use disorder (CanUD). A leave-one-out polygenic risk score (PRS) analysis was performed to compare OUD and OUD-MTAG PRS as predictors of OUD case status in Yale-Penn 3. The EUR meta-analysis identified three genome-wide significant (GWS; p ≤ 5 × 10) lead SNPs-one at FURIN (rs11372849; p = 9.54 × 10) and two OPRM1 variants (rs1799971, p = 4.92 × 10; rs79704991, p = 1.11 × 10; r = 0.02). Rs1799971 (p = 4.91 × 10) and another OPRM1 variant (rs9478500; p = 1.95 × 10; r = 0.03) were identified in the cross-ancestry meta-analysis. Estimated h was 12.75%, with strong r with CanUD (r = 0.82; p = 1.14 × 10) and AUD (r = 0.77; p = 6.36 × 10). The OUD-MTAG resulted in a GWAS N = 128,748 and 18 independent GWS loci, some mapping to genes or gene regions that have previously been associated with psychiatric or addiction phenotypes. The OUD-MTAG PRS accounted for 3.81% of OUD variance (beta = 0.61;s.e. = 0.066; p = 2.00 × 10) compared to 2.41% (beta = 0.45; s.e. = 0.058; p = 2.90 × 10) explained by the OUD PRS. The current study identified OUD variant associations at OPRM1, single variant associations with FURIN, and 18 GWS associations in the OUD-MTAG. The genetic architecture of OUD is likely influenced by both OUD-specific loci and loci shared across SUDs.
尽管阿片类药物使用障碍(OUD)造成了巨大的损失,但迄今为止,对 OUD 的全基因组关联研究(GWAS)仅产生了少数易感基因座。我们在具有欧洲(EUR)和非洲(AFR)血统的个体中进行了 OUD 的大规模 GWAS,通过对与遗传相关的物质使用障碍(SUD)进行 MTAG(GWAS 的多性状分析)来优化遗传信息量。荟萃分析包括七个队列:百万退伍军人计划、精神遗传学联合会、iPSYCH、芬兰遗传学、合作伙伴生物库、BioVU 和耶鲁大学-宾夕法尼亚大学 3,总共包括 639,063 名个体(N=20,686;N=77,026)。OUD 病例的定义是终生 OUD 诊断,对照组是任何不符合 OUD 标准的人。我们估计了 SNP 遗传力(h)和遗传相关性(r)。基于遗传相关性,我们对 OUD、酒精使用障碍(AUD)和大麻使用障碍(CanUD)进行了 MTAG。进行了一项单样本留一多基因风险评分(PRS)分析,以比较耶鲁大学-宾夕法尼亚大学 3 中的 OUD 和 OUD-MTAG PRS 作为 OUD 病例状态的预测因子。EUR 荟萃分析确定了三个全基因组显著(GWS;p≤5×10)的先导 SNP-一个位于 FURIN(rs11372849;p=9.54×10)和两个 OPRM1 变体(rs1799971,p=4.92×10;rs79704991,p=1.11×10;r=0.02)。rs1799971(p=4.91×10)和另一个 OPRM1 变体(rs9478500;p=1.95×10;r=0.03)在跨血统荟萃分析中被确定。估计的 h 为 12.75%,与 CanUD(r=0.82;p=1.14×10)和 AUD(r=0.77;p=6.36×10)具有很强的相关性。OUD-MTAG 产生了一个 GWAS N=128,748 个和 18 个独立的 GWS 基因座,其中一些位于先前与精神或成瘾表型相关的基因或基因区域。OUD-MTAG PRS 解释了 OUD 变异的 3.81%(beta=0.61;s.e.=0.066;p=2.00×10),而 OUD PRS 解释了 2.41%(beta=0.45;s.e.=0.058;p=2.90×10)。目前的研究在 OPRM1 中确定了 OUD 变体关联,在 FURIN 中确定了单一变体关联,并在 OUD-MTAG 中确定了 18 个 GWS 关联。OUD 的遗传结构可能受到 OUD 特异性基因座和 SUD 共有的基因座的影响。